Valley Cottage, NY, April 16, 2016 --(PR.com
)-- Fatty liver disease is the most common liver dysfunction in which the triglyceride fat accumulates in liver cells. The fatty liver disease is caused due to obesity and excessive alcohol intake. Fatty liver is caused due to excessive alcohol intake known as Alcoholic Fatty Liver Disease (ALD) and obesity or insulin resistance known as Non-Alcoholic Liver Disease (NAFLD). The major risk factors associated with fatty liver disease are alcoholic cirrhosis, metabolic syndrome, biliary cirrhosis, progressive liver fibrosis and hepatocellular carcinoma (HCC) as well as increased cardiovascular disorder. Fatty liver disease is currently expected to be the leading cause of hepatocellular carcinoma. The technological advancements and the routine liver function tests are now resulting in the early detection of fatty liver treatment. The increase in incidence of fatty liver disease associated with excessive alcohol intake is expected to create an opportunity for the growth of fatty liver treatment market during the forecast period.
Fatty Liver Treatment Market: Drivers and Restraints
The incidence rate of fatty liver disease particularly the Non-Alcoholic Liver Disease (NAFLD) was estimated to increase approximately by 20 to 25% in 2015. Thus, the market for fatty liver treatment is anticipated to grow significantly during the forecast period. The advancement in technology, personalized medicine, cost effective treatment procedures are few other factors predicted to fuel growth of global fatty liver treatment market. However, the side effects associated with the treatment, and increasing stringency in the regulatory requirements are some of the major factors limiting the growth of global fatty liver treatment market.
Browse Full Report@ http://www.futuremarketinsights.com/reports/fatty-liver-treatment-market
Fatty Liver Treatment Market: Segmentation
The global fatty liver treatment market has been classified on the basis of drugs, end use and geography.
Based on drugs, the global fatty liver treatment market is divided into following:
Polyunsaturated fatty acids
Angiotensin receptor blockers
Based on end user type, the global fatty liver treatment market is divided into following:
Request Free Report Sample@ http://www.futuremarketinsights.com/reports/sample/rep-gb-1369
Fatty Liver Treatment Market: Overview
Due to the availability of variety of agents for fatty liver treatment, the market for overall fatty liver treatment is expected to grow significantly. Additionally, the investment of pharmaceutical companies in the research and development are anticipated to contribute in the growth of fatty liver treatment market. In U.S. it is estimated that more than 15 Mn people are involved in the abuse or over abuse of alcohol and among them more than 90% people suffer from fatty liver disease. Thiazolidinedione and metformin are widely used for the Non-Alcoholic Liver Disease (NAFLD) caused due to insulin resistance. Thus, thiazolidinedione and metformin are expected to highly contribute in the growth of global fatty liver treatment market.
Fatty Liver Treatment Market: Regional Overview
Geographically, the global fatty liver treatment market is classified into regions namely, North America, Latin America, Western Europe, Eastern Europe, APAC, Japan, Middle East and Africa. North America and Europe are expected to dominate the fatty liver treatment market due to abuse cases of alcoholic beverages. APAC is the fastest growing market with increasing prevalence of fatty liver disease associated with factors such as growing alcoholic intake, drug abuse and high prevalence of diabetes. The global fatty liver treatment market is expected to grow remarkably during the forecast period due to increasinginvestment by multinational companies in the research and development.
Download TOC@ http://www.futuremarketinsights.com/toc/rep-gb-1369
Fatty Liver Treatment Market: Key Players
Some of the key players operating in this market are Cardax, Inc., Daewoong Co., Ltd., Hoffmann-La Roche Ltd., Glenmark. GW Pharmaceuticals, Limerick BioPharma, Inc., Merck & Co., Inc., Novartis AG, Orchid Chemicals & Pharmaceuticals Ltd, AstraZeneca.